KNOWLEDGE MAPPING OF PHARMACOECONOMIC ON DIABETES MELLITUS RESEARCH BASED ON SCOPUS DATABASE: A BIBLIOMETRIC ANALYSIS
DOI:
https://doi.org/10.55519/JAMC-01-12479Keywords:
Pharmacoeconomic; Diabetes mellitus; Bibliometric; Scopus; VOSviewerAbstract
Background: Every year there are more people diagnosed with diabetes mellitus (DM). There is no bibliometric report on this subject despite the publishing on the pharmacology of diabetes mellitus. In order to do this, this study will conduct a bibliometrical analysis of the literature on the pharmaco-economic analysis of diabetes therapy. Methods: To find a bibliographic database of primary research on the subject. The Scopus database was searched for articles containing the terms "pharmacoeconomic" OR "cost effectiveness analysis" OR "cost minimization analysis" OR "cost benefit analysis" OR "cost utility analysis" AND "diabetes mellitus" on May 5, 2023. There are 63 documents from the years 1978 to 2023 were chosen. VOSviewer 1.6.16 was used to assess the data. Results: The most significant nations, universities, sources, journals, and authors are, in order of influence: the United Kingdom, Beijing University, Diabetes Care Journal, PharmacoEconomics Journal, and Vijan (United States). A therapy model that is applied with high effectiveness but low cost can be determined by doing a pharmacoeconomic study of all aspects of diabetes mellitus management. Cost-effectiveness and cost-utility are the two most important and varied aspects of this subject. Conclusion: By utilising pharmacoeconomic analysis, our results improve research collaboration and pinpoint the knowledge gaps required for applications in the management of diabetes mellitus.
References
1. Murray CJL. The global burden of disease study at 30 years. Nat Med 2022;28(10):2019–26.
2. Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia 2021;65(1):3–13.
3. Akhtar S, Nasir J, Ali A, Asghar M, Majeed R, Sarwar A. Prevalence of type-2 diabetes and prediabetes in malaysia: a systematic review and meta-analysis. PLoS One 2022;17(1):e0263139.
4. Kohsaka S, Morita N, Okami S, Kidani Y, Yajima T. Current trends in diabetes mellitus database research in Japan. Diabetes Obes Metab 2021;23(S2);3–18.
5. Meo SA, Sheikh SA, Sattar K, Akram A, Hassan A, Meo AS, et al. Prevalence of type 2 diabetes mellitus among men in the middle east: a retrospective study. Am J Mens Health 2019;13(3):155798831984857.
6. Canto ED, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019;26(2):25–32.
7. Liu J, Ren Z, Qiang H, Wu J, Han L, Zhang L, et al. Trends in the incidence of diabetes mellitus: results from the global burden of disease study 2017 and implications for diabetes mellitus prevention. BMC Public Health 2020;20(1):1415.
8. Khan MA, Hashim M, King JC, Govender RD, Mustafa H, Alkaabi J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health 2019;10(1):107.
9. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun XS, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 2020;10(1):14790.
10. Hidayat B, Ramadani RV, Rudijanto A, Soewondo P, Suastika K, Ng JYS. Direct medical cost of type 2 diabetes mellitus and its associated complications in Indonesia. Value Health Reg Issues 2022;28:82–9.
11. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 2015;33(8):811–31.
12. Png ME, Yoong J, Phan, TP, Wee HL. Current and future economic burden of diabetes among working-age adults in asia: conservative estimates for singapore from 2010-2050. BMC Public Health 2016;16(1):153.
13. Ganasegeran K, Hor CP, Jamil MSM, Loh HC, Noor JM, Hamid NA, et al. A systematic review of the economic burden of type 2 diabetes in malaysia. Int J Environ Res Public Health 2020;17(16):5723.
14. Afroz A, Alramadan MJ, Hossain N, Romero L, Alam K, Magliano DJ, et al. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review. BMC Health Serv Res 2018;18(1):972.
15. Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract 2017;6:37–46.
16. Yue X, Li Y, Guo JJ. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in china. Value Health Reg Issues 2021;24:1–5.
17. Alzarea AI, Khan YH, Alanazi AD, Butt MH, Almalki ZS, Alahmari A, et al. Barriers and facilitators of pharmacoeconomic studies: a review of evidence from the middle eastern countries. Int J Environ Res Public Health 2022;19(13):7862.
18. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos, F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract 2021;19(1):2302.
19. Miot J, Thiede M. Adapting pharmacoeconomics to shape efficient health systems en route to uhc – lessons from two continents. Front Pharmacol 2017;8:715.
20. Ramzan S, Timmins P, Hasan SS, Babar Z. Cost analysis of type 2 diabetes mellitus treatment in economically developed countries. Expert Rev Pharmacoecon Outcomes Res 2018;19(1):5–14.
21. Gonçalves AC, Cazarim MdS, Sanches C, Pereira LRL, Lacerda ACR, Aquino JA, et al. Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care 2019;7(1):e000647.
22. Bosetti R, Tabatabai L, Naufal G, Menser T, Kash BA. Comprehensive cost-effectiveness of diabetes management for the underserved in the united states: a systematic review. PLoS One 2021;16(11):e0260139.
23. Su Y, Zhang S, Wu Z, Liu W, Chen J, Deng F, et al. Pharmacoeconomic analysis (cer) of dulaglutide and liraglutide in the treatment of patients with type 2 diabetes. Front Endocrinol (Lausanne) 2023;14:1054946.
24. Krishnamoorthy SG, Shaji JR, Premnath B, Siby AR, Borra SS, Manomohan A, et al. Cost-effectiveness analysis of dapagliflozin versus canagliflozin in treatment of type 2 diabetes mellitus. J Appl Pharm Sci 2022;12(3):171–8.
25. Bamel UK, Pandey R, Gupta A. Safety climate: Systematic literature network analysis of 38 years (1980-2018) of research. Accid Anal Prev 2020;135:105387.
26. Yeung AWK, Heinrich M, Atanasov AG. Ethnopharmacology—a bibliometric analysis of a field of research meandering between medicine and food science? Front Pharmacol 2018;9:215.
27. Elisha IL, Viljoen A. Trends in rooibos tea (Aspalathus linearis) research (1994–2018): A scientometric assessment. South Afr J Bot 2010;137:159–70.
28. Lihitkar SR. Science Mapping and Visualization Tools Used for Bibliometric and Scientometric Studies: A Comparative Study. J Adv Libr Sci 2019;6(1):382–94.
29. Khitous F, Strozzi F, Urbinati A, Alberti F. A systematic literature network analysis of existing themes and emerging research trends in circular economy. Sustainability 2020;12(4):1633.
30. Arifah FH, Nugroho AE, Rohman A, Sujarwo W. A bibliometric analysis of preclinical trials of Andrographis paniculata (Burm.f.) Nees in diabetes mellitus. S Afr J Bot 2022;151:128–43.
31. van Eck NJ, Waltman L. VOSviewer (version 1.6.16) [software]. [Internet]. Leiden: Leiden University; 2020. [cited 2023 Sep]. Available from: https://www.vosviewer.com/
32. Ramamoorthi R, Gahreman D, Skinner T, Moss S. Bibliometric profile and density visualizing analysis of yoga intervention in type 2 diabetes: A 44 -year study on global scientific research output from 1975 to 2019. Int J Yoga 2021;14(2):89–99.
33. Yeung AWK, Tzvetkov NT, Durazzo A, Lucarini M, Souto EB, Santini A, et al. Natural products in diabetes research: Quantitative literature analysis. Nat Prod Res 2020;35(24):5813–27.
34. Qin Y, Xu Z, Wang X, Škare M. Green energy adoption and its determinants: A bibliometric analysis. Renew Sustain Energy Rev 2022;153:111780.
35. Tan H, Li J, He M, Li J, Zhi D, Qin F, et al. Global evolution of research on green energy and environmental technologies:A bibliometric study. J Environ Manage 2021;297:113382.
36. Ma R. Author bibliographic coupling analysis: A test based on a Chinese academic database. J Informetr 2012;6(4):532–42.
37. Abdullah, Khan MN. Determining mobile payment adoption: A systematic literature search and bibliometric analysis. Cogent Bus Manag 2021;8(1):1–21.
38. Perianes-Rodríguez A, Waltman L, Van Eck NJ. Constructing bibliometric networks: a comparison between full and fractional counting. J Informetr 2016;10(4):1178–95.
39. Cheng KH, Tang KY, Tsai CC. The mainstream and extension of contemporary virtual reality education research: Insights from a co-citation network analysis (2015–2020). Educ Technol Res Dev 2022;70(1):169–84.
40. Shiau WL, Dwivedi, YK, Yang, HS. Cocitation and cluster analyses of extant literature on social networks. Int J Inf Manag 2017;37(5):390–9.
41. Grames EM, Stillman AN, Tingley MW, Elphick CS. An automated approach to identifying search terms for systematic reviews using keyword co‐ occurrence networks. Methods Ecol Evol 2019;10(10):1645–54.
42. Vargas-Quesada B, Chinchilla-Rodríguez Z, Rodriguez N. Identification and Visualization of the Intellectual Structure in Graphene Research. Front Res Metr Anal 2017:2:7.
43. Zhang J, Yu Q, Zheng F, Long C, Lu Z, Duan Z. Comparing keywords plus of WOS and author keywords: A case study of patient adherence research: Comparing Keywords Plus of WOS and Author Keywords. J Assoc Inf Sci Technol 2016;67(4):967–72.
44. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283(7):889–96.
45. Hoerger TJ, Harris R, Hicks K, Donahue KE, Sorensen SW, Engelgau MM. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140(9):689–99.
46. Elixhauser A, Weschler JM, Kitzmiller JL, Marks JG, Bennert HW, Coustan DR, et al. Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care 1993;16(8):1146–57.
47. Starostina EG, Antsiferov MB, Drapkina OM, Trautner C, Jörgens V, Bott U, et al. Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for type 1 (insulin-dependent) diabetes mellitus in moscow—blood glucose versus urine glucose self-monitoring. Diabetologia 1994;37(2):170–6.
48. Davies MJ, Chubb B, Smith IC, Valentine WJ. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med. 2012;29(3):313–20.
49. Foster RH, Plosker GL. Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics. 2000;18(3):289–306. Ref no 49&50 are same
50. Foster RH, Plosker GL. Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics. 2000;18(3):289–306. Ref no 49&50 are same
51. Nicholson WK, Fleisher LA, Fox H, Powe NR. Screening for gestational diabetes mellitus. Diabetes Care. 2005;28(6):1482–4.
52. Poncet B, Touzet S, Rocher L, Berland M, Orgiazzi J, Colin C. Cost-effectiveness analysis of gestational diabetes mellitus screening in France. Eur J Obstet Gynecol Reprod Biol 2002;103(2):122–9
53. Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a chinese population with type 2 diabetes mellitus. Curr Med Res Opin 2017;33(2):359–69.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Fiqri Zulpadly, Heru Sasongko, Dian Eka Ermawati
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
